Answers are grounded in this paper and cite their sources.
IL-32 synthesis by FLSs is tightly regulated by innate immunity in rheumatoid arthritis. Thus TNF-α, IFN-γ, double-strand RNA, hyaluronic acid, or other damage-associated molecular patterns (DAMPs), highly secreted in synovial tissues of RA patients, might trigger IL-32 secretion by FLSs. IL-32 might therefore represent a relevant therapeutic target in RA.
No takes yet. Share an insight, caveat, or question.
Alsaleh et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: